Glaxo to Evaluate Quantum Dot SNP Detection System | GenomeWeb

NEW YORK, Jan 16 - Quantum Dot said Tuesday that GlaxoSmithKline has agreed to help in evaluating the company’s SNP detection assays.

Financial terms of the deal were not disclosed. Andy Watson, vice president of systems at QDC, said the evaluation could potentially lead to a licensing agreement.

"They’ll be using their expertise to evaluate the data we generate and to see how applicable it is to their needs," said Watson.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.